Introduction
============

Multiple myeloma (MM) is the second most widespread hematological cancer; it is characterized by the accumulation of malignant plasma cells within the bone marrow.

Despite the survival improvement brought by current treatments, the majority of patients relapses and succumbs to the disease with a median survival of 6 years [@B1].

MM is a highly heterogeneous disease at genetic and clinical levels [@B2]-[@B4]. Recent studies, using next-generation sequencing, have revealed the complex mutational landscape of MM patients as well as a considerable intraclonal heterogeneity in association with drug resistance and tumor progression [@B5]-[@B7]. Given these observations, the improvement of MM treatment might come from personalized medicine, taking into account the patients\' genetic background [@B6].

A major difficulty in advancing the understanding of drug resistance in MM is the availability of primary tumor cells. MM cells can survive for several days of culture, but cannot be expanded *in vitro* for the vast majority of patients. This represents a serious limitation for a meaningful biological study on the resistance mechanisms. An alternative strategy is to use MM cell lines as an unlimited source of tumor cells.

Human multiple myeloma cell lines (HMCLs) have been widely used for the understanding of MM biology, the identification and validation of target genes, and the screening of potential anti-myeloma drugs. However, biological studies in MM are often performed with a restricted number of HMCLs that are poorly characterized at the molecular level and do not reflect the heterogeneity of MM patients. In the past few years, we have derived a large cohort of patient-derived HMCLs that remain dependent on the addition of exogeneous MM growth factors, thereby reflecting primary tumor conditions [@B8]. Using these myeloma cell lines, we recently described that they recapitulate the molecular heterogeneity found in MM primary tumors by analyzing the gene expression profile [@B8]. However, the mutational landscape of human myeloma cell lines has never been described.

A comprehensive characterization of genomic mutations in myeloma cell lines would advance our understanding of myeloma pathophysiology and could also provide a basis for choosing relevant cell line models to study a particular aspect of myeloma biology, or to screen for an antagonist of specific cancer pathways.

In this study, we present, for the first time, the mutational landscape of human myeloma cell lines. We conducted whole-exome sequencing (WES) on 30 HMCLs, representative of the molecular heterogeneity of MM, and 8 control samples (EBV-immortalized B-cells from 8 of the same patients). We identified a high confidence list of 236 protein-coding genes with mutations likely affecting the structure of the encoded protein. These genes include well-known MM drivers such as the tumor suppressor *TP53*, the MAPK pathway (*KRAS*, *NRAS* and *BRAF*), the ataxia-telangiectasia mutated (*ATM*), cyclin D1 (*CCND1*), the RB transcriptional corepressor (*RB1*) and the family with sequence similarity 46 Member C (*FAM46C*) [@B6],[@B9]. Additionally, we identified novel mutated genes involved in key pathways, including JAK-STAT, PI(3)K-AKT, DNA repair and chromatin modifier pathways. Interestingly, we found that mutations in *KRAS*, *FAM46C, KMT2D, PMS1* and*USP6* were significantly associated with drug resistance.

Methods
=======

Samples
-------

XGs human myeloma cell lines (HMCLs) were obtained as previously described [@B8]. AMO-1, LP1, L363, OPM2, MOLP2, MOLP8, Lopra and SKMM2 were purchased from DSMZ (Braunsweig, Germany) and RPMI8226 from ATCC (American Tissue Culture Collection, Rockville, MD, USA). JJN3 was kindly provided by Dr. Van Riet (Bruxelles, Belgium) and MM1S by Dr. S. Rosen (Chicago, USA). HMCLs were authenticated according to their short tandem repeat profiling and their gene expression profiling using Affymetrix U133 plus 2.0 microarrays deposited in the ArrayExpress public database under accession numbers E-TABM-937 and E-TABM-1088. HMCLs characteristics, obtained from previously published analysis results [@B8], are available in **Table [S1](#SM0){ref-type="supplementary-material"}**. EBV-immortalized B-cells from 8 different patients have been used as control cells. The patients are those from whom the XG1, XG3, XG5, XG10, XG13, XG14, XG16 and XG19 cell lines were generated.

WES
---

WES was performed on 30 HMCLs and 8 control samples (EBV-immortalized B-cells from 8 of the same patients). We also performed and analyzed the WES of purified primary MM cells from 59 patients in order to compare mutated genes between HMCLs and primary tumor cells. Forty-three newly diagnosed patients and patients at relapse (N=16) were treated by high-dose chemotherapy plus autograft. Lines of treatments of patients at relapse were described in **Table [S2](#SM0){ref-type="supplementary-material"}**. Bone marrow samples were collected after patients\' written informed consent in accordance with the Declaration of Helsinki and institutional research board approval from Montpellier University hospital (DC-2008-417).

The WES library preparation was done with 1000 ng of input DNA. Sequences of exome were enriched using SureSelect^xt^ kit and SureSelect^xt^ All Exons v5 library (Agilent Technologies, Santa Clara, California, USA). Paired-end exome sequencing was performed on the enriched exome sequences using the illumina NextSeq500 sequencing instrument (Helixio, Clermont-Ferrand, France), generating 75 bp paired-end reads with 100X average coverage per sample.

Analysis of single nucleotide variants
--------------------------------------

The workflow of data analysis is illustrated in **Figure [1](#F1){ref-type="fig"}A**. Read pairs were mapped to the reference human hg19 genome using the Bowtie 2 aligner version 2.3.2 [@B10]. SAMTools version 1.5 [@B11] was used to convert Sequence Alignment Map (SAM) files to sorted Binary Alignment Map (BAM) files. Indel Realignment and base quality recalibration steps were completed with GATK 3.8-1 [@B12]. BCFtools version 1.5 [@B11] was utilized to detect variants from the BAM file and outputs into a Variant Call Format (VCF) file. We used ANNOVAR version 2017Jul16 [@B13] to annotate the variants. Mutations were determined by applying a series of filters on the ANNOVAR output. Firstly, we filter out mutations present in control EBV (Epstein-Barr Virus) samples and in dbSNP database (version 138). Synonymous and intronic variants as well as mutations located in segmental duplications were removed, along with variants present in greater than 1% of the 1000 genome project [@B14] and/or Exome Sequencing Project (ESP6500). Secondly, we prioritize mutations by filtering them based on four deleterious predictors included in the ANNOVAR software (SIFT, PolyPhen2, FATHMM and LRT). Variants are considered for further analyses only if they are predicted deleterious by at least one of the deleterious predictors. Finally, we retain only mutations that were present in COSMIC [@B15] and/or OncoKB [@B16] databases. The MAF (Mutation Annotation File Format) file format was used to store the genomic mutations of the different cell lines in the same file. We used the maftools [@B17] R/Bioconductor package to summarize, analyze and visualize the MAF files. Copy Number Variations (CNV) and IgH translocations were determined by the CNV-seq method [@B18] and fluorescence in situ hybridization (FISH) [@B8],[@B19], respectively. Significant mutual exclusive mutations were assessed with the maftools R package [@B17]. The subclonal heterogeneity was inferred by clustering variants according to their allele frequencies using maftools R package [@B17]. The subclonal heterogeneity could be inferred by clustering variants according to their allele frequencies [@B20],[@B21]. inferHeterogeneity function uses density based finite or infinite (dirichlet process) mixture models, to cluster and classify variants into subclones [@B22],[@B23]. The presence of different subclones are visualized using density plots of variant allele fraction VAF. Variants on copy number altered regions were excluded. Pathway enrichment analyses were performed using the R package ReactomePA [@B24] and Kegg database [@B25]-[@B27].

HMCLs response to drug treatment
--------------------------------

HMCLs were cultured in RPMI-1640 medium (Gibco, Thermo Fisher Scientific, Waltham, Massachusetts, USA) supplemented with fetal bovine serum (FBS, Eurobio, Les Ulis, France) (10%) and Interleukin 6 (IL6, Peprotech, Rocky Hill, New Jersey, USA) for XG cell lines. We evaluated the sensitivity of the cell lines to ten drugs, including Bortezomib (Euromedex), Melphalan (HAC Pharma), Lenalidomide (Selleckchem), Pomalidomide (Selleckchem), IKK2 inhibitor (AS602868), CDK inhibitor (AT7519 CDK1/2/4/5/6/9i, Selleckchem), TSA (Trichostatin A, HDACi, Sigma), SAHA (Suberanilohydroxamic acid, HDACi, Selleckchem), Panabinostat (HDACi, Selleckchem) and Dexamethasone. For a given drug, HMCLs were treated with different concentrations. The IC~50~was determined at day 4 using the CellTiter-Glo assay (Promega, Madison, Wisconsin, USA), as previously described [@B28],[@B29]. The data represent the mean ± standard deviation of three independent experiments that were carried out on sextuplet culture wells (**Table [S3](#SM0){ref-type="supplementary-material"}**). The subset of HMCLs used for analyses were characterized, for drug response, in previous studies [@B28],[@B30]-[@B34] and selected according to the different molecular subgroups previously described by transcriptomic analyzes [@B8].

Statistical analyses
--------------------

All statistical calculations were carried out using the R software (R Foundation for Statistical Computing, Vienna, Austria). The classification of HMCLs into multiple groups based on their mutation profile was done by unsupervised multiple correspondence analysis (MCA) and hierarchical clustering using the R packages FactoMineR [@B35] and factoextra [@B36]. Wilcoxon test was used to evaluate the significance of the association between mutated genes and response to treatment.

Results
=======

Landscape of mutations in HMCLs
-------------------------------

We performed WES on 30 HMCLs as well as on EBV-immortalized B-cells from 8 patients (used to derive 8 XGs cell lines), which are used as control cells. However, no cell line represents a hyperdiploid subgroup. Two cell lines, XG16 and XG27, are characterized by the absence of recurrent translocation. XG16 is characterized by chromothripsis, including a huge number of chromosomal rearrangements involving localized genomic regions; it is associated with poor outcome in MM [@B37].

First, we sought to identify exonic variants, non-synonymous variants and variants predicted to be deleterious, as these are the candidates for cancer pathogenesis and drug targets. We identified 9570 non-synonymous exonic mutations in the cell lines, as specified in the Methods section. These mutations involve a total number of 4743 unique genes. Next, we focused on mutations present in COSMIC and/or OncoKB databases, which contain previously reported, mutated genes in cancers or those having oncogenic functions. We identified a high confidence list of 236 protein coding genes with mutations affecting the structure of encoded protein (**Table [S4](#SM0){ref-type="supplementary-material"}**). In these genes, we detected 576 variants (range: 8 - 32; median: 19 per cell lines), including 468 point mutations and 108 insertions/deletions (INDELS). The point mutations include 459 missense and 9 nonsense mutations (**Figure [S1](#SM0){ref-type="supplementary-material"}A-B**). Ranking by mutation type indicates an excess of C \> T transitions (**Figure [S1](#SM0){ref-type="supplementary-material"}C**).

As recurrently mutated genes in HMCLs could represent novel candidate driver genes in MM progression, we investigated the most frequently mutated genes in HMCLs. The top 50 most frequently mutated genes are illustrated in **Figure [1](#F1){ref-type="fig"}B**. Twenty-two of the 50 genes were mutated in at least 5 out of the 30 cell lines (17%). These genes include *TP53* (47%), *CNOT3* (43%), *KRAS* (37%), *KMT2D* (33%), *NRAS* (30%), *ATM*, *MN1* and *MSH3* (27%), *FAM46C* (23%), *KMT2B* and *SETD2* (20%), and *EZH2* and *PMS1* (17%). Importantly, some of these genes, *TP53*, *KRAS*, *NRAS*, *ATM*, and *FAM46C*, have been previously reported to be a target of recurrent mutations in newly diagnosed MM patients [@B6],[@B9]. Notably, 86% of the frequently mutated genes in HMCLs were also found to be mutated in at least one primary tumor sample from myeloma patients (**Figure [2](#F2){ref-type="fig"}A-B**). One hundred and seventy-nine out of the 236 (76%) identified mutations were also described in primary MM cells from newly diagnosed patients in previous studies [@B6],[@B9],[@B38],[@B39]. Among them, *CIC, KRAS* and*NRAS* were the most frequently mutated genes in patients and were identified at diagnosis (**Figure [2](#F2){ref-type="fig"}A**) and relapse (**Figure [2](#F2){ref-type="fig"}B**). Interestingly, *FAM46C* mutation was more frequent at relapse than at newly diagnosed patients, underlying its role as a myeloma driver gene. *KMT2D* and *SETD2* were mutated only in patients at relapse (**Figure [2](#F2){ref-type="fig"}A-B**). Fourty percent of the mutations identified in patients present at a higher frequency in HMCLs, including *TP53*, *CNOT3* and *KMT2D* mutations (**Table [S5](#SM0){ref-type="supplementary-material"}**). Moreover, variant allele frequency analysis of mutated genes revealed that HMCLs present one to four subclones, a range that was comparable to MM patients samples (**Table [S6](#SM0){ref-type="supplementary-material"}A-B**). This is consistent with previous results demonstrating that HMCLs derived in the presence of IL-6 display a molecular heterogeneity which overlaps one of MM patients [@B8].

Further analyses were performed, using the 22 frequently mutated genes, to classify HMCLs into multiple groups based on their mutational profile. Unsupervised MCA followed by hierarchical clustering produced 2 major dendrogram branches with 5 subgroups (**Figure [3](#F3){ref-type="fig"}A**). Group 1 (LP1, OPM2, SKMM2, XG26, XG23, XG24, L363, XG1, XG16, XG12, and XG13) is mainly characterized by *NRAS*, *CNOT3* and*LRP1B* mutated (MUT) and *KRAS*, *MN1*, *ATM*, *USP6* and*KMT2B* wild type (WT) genes; group 2 (XG25 and XG7) is associated with mutations in *PMS1*, *USP6*, *SETD2*, *KMT2B* and*FAM46C*; group 3 (RPMI, XG11, XG29, Lopra, XG27, MM1S, AMO1, XG20, and XG6) is mainly characterized by the presence of mutations in *KRAS*,*ATM* and *MN1* as well as*CNOT3* WT; group 4 (XG19, JJN3, XG2, and XG28) is characterized by *KMT2B* mutations; cell lines of group 5 (MOLP8, XG5, MOLP2, and XG30) were associated with mutations in*MAP3K1*, *EZH2* and *SETD2* (**Figure [3](#F3){ref-type="fig"}A**). We investigated the link between the groups defined by the mutational profile and major MM cytogenetic abnormalities (**Figure [3](#F3){ref-type="fig"}B**). No significant association between the molecular heterogeneity defined by the mutational profile and the recurrent IgH translocations was identified (**Figure [3](#F3){ref-type="fig"}B**). Del1p, 1q gain, del13q and del17p were respectively found in 70%, 50%, 56% and 43% of HMCLs. Notably, 10 cell lines are characterized by TP53 mutation and del17p underlining HMCLs with *TP53* bi-allelic event, known to be associated with a dramatic impact on survival in MM (**Table [S1](#SM0){ref-type="supplementary-material"}**) [@B40]. Furthermore, 5 cell lines are associated with del1p and *FAM46C* mutations double-hit events (**Table [S1](#SM0){ref-type="supplementary-material"}**) [@B40].

Mutations in key pathways controlling cell growth
-------------------------------------------------

Many canonical pathways known to be involved in MM cell survival and proliferation were mutated, including JAK-STAT, PI(3)K-AKT and MAPK (**Figure [4](#F4){ref-type="fig"}A**). Mutation of genes involved in the MAPK pathway was the most prevalent (25/28 HMCLs, 89%). In this pathway, the most frequently mutated genes were *KRAS* (39%), *NRAS* (32%), *MAP3K1* (18%) and *BRAF* (11%) (**Figure [5](#F5){ref-type="fig"}A**). In addition to these recurrently mutated genes, we found occasional mutations in other genes involved in MAPK signaling, including *MAP2K2* (7%), *RAC1* (4%), *RAF1* (4%) and *NF1* (4%). Mutations in *KRAS* and *NRAS* were mutually exclusive (**Figure [S2](#SM0){ref-type="supplementary-material"}A**). This suggests that mutations occurring simultaneously in these genes might be lethal for cancer cells or that the second mutation did not confer a selective advantage. According to that, *KRAS* and *NRAS* mutations could represent good candidates for therapies based on synthetic lethality. Mutations in the JAK-STAT pathway included *STAT3* (11%), *RUNX1* (11%), *EPAS1* (7%), *JAK3* (7 %) and *STAT6* (4%) (**Figure [4](#F4){ref-type="fig"}A and [5](#F5){ref-type="fig"}A**). Mutated genes in the PI(3)K-AKT pathway include *TSC2* (11%), *TBX3* (7%), *PTEN* (7%), *IKBKB* (4%) and *TSC1* (3%). Notably, several receptors activating these pathways were also mutated, including *ERBB3* (14%), *EGFR* (11%) and *IGF1R* (11%) (**Figure [4](#F4){ref-type="fig"}A and [5](#F5){ref-type="fig"}A**). Additionally, mutations in p53/cell-cycle pathway were detected in 76% of the cell lines (**Figure [4](#F4){ref-type="fig"}B and [5](#F5){ref-type="fig"}B**). The most recurrently mutated genes include *TP53* (61%), *ATM* (35%), *CCND1* (13%), *CDKN2A* (13%) and *RB1* (9%). Importantly, mutations in *CCND1*, *TP53* and *ATM* are associated with a negative impact on survival [@B38].

Mutations in DNA repair pathways
--------------------------------

DNA repair is one of the most important biological mechanisms involved in cancer development and drug resistance [@B41]. Depending on the type of DNA damage, specific DNA repair pathways are used to restore genetic information. Base excision repair (BER), nucleotide excision repair (NER) and mismatch repair (MMR) operate on nucleotide lesions occurring on single strands. For double-strand breaks, there are two major pathways, including non-homologous end-joining (NHEJ) and homologous recombination (HR). The alteration of DNA repair pathways can promote tumorigenesis and can induce drug resistance. Notably, multiple lines of evidence underlie the close link between DNA damage repair pathways and response to treatment in MM as well as patients\' survival [@B38],[@B42],[@B43]. Our analysis revealed mutations in 16 DNA repair genes (**Figure [6](#F6){ref-type="fig"}A and [7](#F7){ref-type="fig"}A**). *ATM* is the most frequently mutated DNA repair gene (MR: 38%), mainly with missense mutations. Other frequently mutated DNA repair genes include *MSH3* (38%; in frame insertion, frame deletion and missense), *PMS1* (24%; missense and frame shift insertion) and *FANCG* (10%; missense). In addition to these recurrently mutated genes, we found occasional mutations in other key genes: *TP53BP1*, *BLM*, *BRCA1*, *ERCC4*, *FANCA*, *FANCD2*, *FANCF*, *MLH1*, *MUTYH*, *PMS2*, *WRN* and *XPA* (**Figure [6](#F6){ref-type="fig"}A and [7](#F7){ref-type="fig"}A**).

Mutations in epigenetic modifiers
---------------------------------

Our analysis revealed mutations in several chromatin-modifying or chromatin-regulatory key genes, including histone demethylases (*KDM5C*, *KDM5A*, and *KDM6A*), histone methyltransferases (*KMT2A/B/C/D*, *EZH2*, and *SETD2*), genes in polycomb complex (*ASXL1/L2* and *MGA*) and SWI/SNF chromatin remodeling complex (*ARID1A* and *ARID1B*). *KMT2D*, *KMT2B*, *SETD2*, *ARID1B* and *EZH2* were the most frequently mutated genes with various types of alterations (**Figure [6](#F6){ref-type="fig"}B and [7](#F7){ref-type="fig"}B**).

Evaluating the association between HMCL mutation profile and response to treatment
----------------------------------------------------------------------------------

We analyzed the relationship between the mutational status of HMCLs and response to conventional drugs in MM (Bortezomib, Melphalan, Dexamethasone and IMiDs) as well as targeted inhibitors (HDAC, CDK and IKK inhibitors). Three pan-HDAC inhibitors have been tested, including Panobinostat, SAHA and TSA.

Importantly, we found a significant (p-value \< 0.05) association between several key mutated genes and resistance to drugs, including Panobinostat (*FAM46C* and*KRAS*), Dexamethasone (*KMT2D*), TSA *(PMS1)* and SAHA (*USP6*) (**Figure [8](#F8){ref-type="fig"}A**).

Additionally, other gene mutations were significantly (p-value \< 0.05) related to drug sensitivity, including Lenalidomide (*KMT2D* and *TP53*) and Panobinostat (*TP53*) (**Figure [8](#F8){ref-type="fig"}B**). Recently, Sievers et al. described key proteins required for the anti-myeloma effects of IMiDs using a CRISPR-Cas9 screen [@B44]. Investigating mutations in the network involved in IMiDs activity, we identified mutations of *CAND1*, *IKZF1*, *IKZF3*, *NCOR1*, *EDC4*, *PPP6C*, *UBE2D3* and *UBE2M* in our panel of cell lines (**Figure [9](#F9){ref-type="fig"}A-B**). Of major interest are HMCLs with a mutation of at least one of these genes that exhibited a significant, 5.4-fold higher resistance to pomalidomide (**Figure [9](#F9){ref-type="fig"}B**).

Taken together, this analysis has highlighted key genes with potential importance in drug resistance in MM. Further biological studies will be needed to understand the role of these genes in MM cell response to treatment.

Discussion
==========

HMCLs are invaluable biomedical research tools that have been extensively used to understand MM physiopathology as well as for drug screening. In this study, we report, for the first time, the mutational landscape of the largest HMCLs cohort to date, which is a representative of the large molecular spectrum of the disease. We identified a list of 236 mutated protein-coding genes, including genes involved in critical pathways such as MAPK (*KRAS*, *NRAS*, *MAP3K1* and *BRAF*) (**Figure [4](#F4){ref-type="fig"}A and [5](#F5){ref-type="fig"}A**), JAK-STAT (*RUNX1*, *STAT3*, *EPAS1*, *JAK3* and *STAT6*) (**Figure [4](#F4){ref-type="fig"}A and [5](#F5){ref-type="fig"}A**), PI(3)K-AKT (*PTEN*, *TSC1/2*, *TBX3* and*IKBKB*) (**Figure [4](#F4){ref-type="fig"}A and [5](#F5){ref-type="fig"}A**), TP53/cell cycle (*TP53*, *CCND1*, *CDKN2A* and *RB1*) (**Figure [4](#F4){ref-type="fig"}B and [5](#F5){ref-type="fig"}B**), DNA repair pathways (*ATM*, *MSH3*, *PMS1* and *FANCG*) (**Figure [6](#F6){ref-type="fig"}A and [7](#F7){ref-type="fig"}A**) and chromatin modifiers (*KMT2D*, *KMT2B*, *SETD2*, *ARID1B* and *EZH2*) (**Figure [6](#F6){ref-type="fig"}B and [7](#F7){ref-type="fig"}B**), as well as in growth factor receptors (*ERBB3*, *EGFR* and *IGF1R*) (**Figure [4](#F4){ref-type="fig"}A and [5](#F5){ref-type="fig"}A**).

Importantly, among the most recurrently mutated genes in HMCLs, there were the previously identified genes in primary MM cells, including *TP53 (47%)*, *KRAS* (37%), *NRAS* (30%), *ATM* (27%) and *FAM46C* (23%) (**Figure [1](#F1){ref-type="fig"}B**)[@B6],[@B9]. Mutations in CCR4-NOT Transcription Complex Subunit 3 (*CNOT3*, 43%) and the Lysine Methyltransferase 2D (*KMT2D*, 33%) also appear at high frequencies, highlighting their potential importance in MM tumor progression.

*CNOT3* is part of the CCR4-NOT complex, which is one of the major deadenylases in eukaryotes. Thus, *CNOT3* plays an important role in mRNA stability regulation [@B45]. Moreover, *CNOT3* has been shown to contribute in early B cell development through the regulation of p53 mRNA stability and Igh rearrangement [@B45]. In addition, *CNOT3* has been identified as a tumor suppressor in T-ALL [@B46].

*KMT2D* has recently emerged as one of the most frequently mutated genes in a variety of cancers [@B47]. Additionally, *KMT2D* is involved in normal B cell differentiation; *KMT2D* deregulation promotes lymphomagenesis [@B48]. Mutations in *KMT2D* identified thus far point to its loss-of-function in pathogenesis and suggest its role as a tumor suppressor in various tissues. Previous studies support that *KMT2D* has distinct roles in neoplastic cells, as opposed to normal cells, and that inhibiting *KMT2D* may be a viable strategy for cancer therapeutics [@B47],[@B48].

Other novel mutated genes with potential importance in MM biology include *PTPRD* (Protein Tyrosine Phosphatase, Receptor type D, 23%) (**Figure [1](#F1){ref-type="fig"}B**), *LRP1B* (LDL Receptor-Related Protein 1B, 23%) (**Figure [1](#F1){ref-type="fig"}B**), *SETD2* (SET Domain Containing 2, 20%) (**Figure [1](#F1){ref-type="fig"}B, 6B and 7B**), *EZH2* (Enhancer of Zeste 2 Polycomb Repressive Complex 2, 17%) (**Figure [1](#F1){ref-type="fig"}B, 6B and 7B**) and*FANCG* (FA Complementation Group G, 7%) (**Figure [6](#F6){ref-type="fig"}A and [7](#F7){ref-type="fig"}A**). *PTPRD* is a protein tyrosine phosphatase signaling molecule that is known to be involved in oncogenic transformation. It has been reported as frequently lost in many cancers and is associated with tumor-suppressor activity [@B49]. *LRP1B* belongs to the low-density lipoprotein (LDL) receptor family*. LRP1B* is a putative tumor suppressor and *LRP1B* silencing has been observed in renal and thyroid cancers [@B50],[@B51]. Mutations in *SETD2* have been found in 12% of B-cell acute lymphoblastic leukemia and in a range between 1% and 2% of B-cell lymphoma; they have also been found in chronic lymphocytic leukemia and acute myeloid leukemia (AML) [@B52]. More recently, *SETD2* mutations were also reported in MM [@B39]. This gene has a key role in DNA repair since it is required for DNA mismatch repair and for DNA double-strand break repair [@B53],[@B54]. Moreover, it has been shown that *SETD2* mutations lead to resistance to DNA-damaging agents in leukemia [@B55]. *EZH2* (Enhancer of Zeste 2 Polycomb Repressive Complex 2) is known to be deregulated in MM [@B56]. Recently, few studies highlighted the interest to target *EZH2*, with or without being associated with other drugs such as Bortezomib or IMiDs, to overcome MM drug resistance [@B30],[@B57],[@B58]. *FANCG* is involved in Fanconi anemia, a disorder that is characterized by an impaired bone marrow function and that predisposes to AML [@B59]. Furthermore, high expression of Fanconi anemia genes is associated with poor prognosis in B cell malignancies, including MM [@B42],[@B60].

Altogether, these data underline mutations of reported tumor suppressor genes that may play a key role in MM progression. It will be of interest to investigate multi-omics analyses integrating RNA-seq, mutations and single nucleotide polymorphisms (SNP) analyses to identify significant associations between genetic abnormalities in this large cohort of MM cell lines.

Interestingly, our analysis reveals that HMCLs present one to four subclones, a range that is similar to primary tumor samples (**Table [S6](#SM0){ref-type="supplementary-material"}A-B**). These results suggest that HMCLs can be used to study the effect of MM treatments on subclonal evolution, which is critical to understand the mechanisms underlying relapse from chemotherapy and drug resistance. In this context, analysis of the subclonal composition and phylogenetic pattern of the HMCLs at single cell level will be of particular interest [@B61].

It is noteworthy that our analysis highlighted mutual exclusive mutations in HMCLs between *KRAS* and *NRAS*, implying that they did not occur together in the same cell lines. Mutual exclusivity is important for the understanding of cancer progression and functional relationships between the alterations. Moreover, genes mutated in a mutually exclusive fashion can be interesting for targeted treatment through a synthetic lethality approach [@B62].

We also identified 10 HMCLs characterized by *TP53* bi-allelic events and 5 HMCLs presenting del1p and *FAM46C* mutation double hits (**Table [S1](#SM0){ref-type="supplementary-material"}**). These cell lines represent a potent model to identify therapeutic strategies in order to improve the survival of patients characterized by these bi-allelic inactivations and poor outcome [@B40].

HMCLs are potent tools not only to study molecular mechanisms underlying MM but also for first-line tests to decipher drug effects on MM cells. In this study, we found a significant association between mutated genes and drug resistance or sensitivity. These genes include *FAM46C*, *KMT2D*, *KRAS*, *PMS1*, *USP6* and *TP53* (**Figure [8](#F8){ref-type="fig"}A-B**). Further studies are needed to validate their biological role in treatment response. *FAM46C* is described as one of the most frequently mutated genes in MM in several studies and its function is largely unknown [@B63]. Recently, it has been described as a potential onco-supressor and a non-canonical poly(A) polymerase specific to B-cell lineage [@B63]. Furthermore, double-hit events involving *FAM46C* are associated with poor outcome in MM patients after relapse [@B40]. *FAM46C* mutation was associated with higher resistance of HMCLs to Panobinostat, an histone deacetylase inhibitor (HDACi). HDACi are known to activate NFκB through inhbition of *HDAC3*-mediated deacetylation of the p65/RelA NFκB subunit [@B64]. This NFκB activation by HDACi participated in the biological rationale of combining HDACi with proteasome inhibitors in MM [@B65]. According to that, MM cells with *FAM46C* mutations could be associated with lower dependence on NFκB pathway. Notably, we also found significant associations between *TP53* mutations and sensitivity to Panobinostat and Lenalidomide (**Figure [8](#F8){ref-type="fig"}B**). These data underlined previous observations indicating that MM cells sensitive to Panobinostat are significantly enriched in genes related to high tumor metabolism and growth compared to resistant ones associated with a more quiescent state [@B28]. *TP53* bi-allelic event is also associated with a dramatic impact on survival in MM patients after relapse, whereas *TP53* mutations were not associated with a prognostic impact [@B40]. The higher sensitivity of *TP53* mutated HMCLs to Panobinostat HDACi and Lenalidomide could be of clinical interest in MM patients with *TP53* MM driver mutations. Furthermore, mutations in genes required for IMiD-mediated CRL4^CRBN^ activity [@B44] have been found to be associated with significant resistance to pomalidomide in our panel of HMCLs. These genes included *IKZF1* and *IKZF3* that are ubiquitinated and degraded by CRL4^CRBN^, *CAND1* and *UBE2M* cullin-RING ligase regulators, *UBE2D3* E2 ubiquitin-conjuating enzyme and other genes of unclear function (*PPP6C*, *NCOR1* and *EDC4*) (**Figure [9](#F9){ref-type="fig"}**). These data illustrate the mechanistic importance of acquired mutations in known genes required for IMiD-mediated toxicity and could open new avenues of therapies aimed at overcoming these processes.

Conclusions
===========

In summary, this study provides a comprehensive map of mutations in HMCLs. Our data provide unique resources for further studies and could help identify novel, critical genes and pathways potentially associated with MM progression. The determination of actionable mutations potentially associated with drug resistance/sensitivity may open the way for alternative targeted treatments.
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:   acute myeloid leukemia

BAM

:   binary alignment map
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:   base excision repair

EBV
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FBS
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HMCLs

:   human myeloma cell lines
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:   mutated
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:   nucleotide excision repair
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:   non-homologous end joining

SAHA
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:   sequence alignment map

TSA
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VCF

:   variant call format

WES

:   whole exome sequencing
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T-ALL
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![**Analysis workflow and human myeloma cell lines (HMCLs) mutational landscape. (A)** Exome sequencing data from MM cell lines and control samples EBV-immortalized B-cells were processed in three steps (alignment, variant calling and variant annotation). In order to find mutations, obtained variants were filtered according to four criteria described in the methods section. Mutations were prioritized using four deleterious predictors included in the ANNOVAR software (SIFT, PolyPhen2, FATHMM and LRT). Mutated genes present in COSMIC and/or OncoKB databases were kept for further analyses. Selected mutated genes were analyzed with the R package MAFtools. Pathway enrichment analysis was done with R package ReactomePA and Kegg database. HMCLs were classified into groups based on their mutational profile using the R packages FactoMineR and factoextra. **(B)** Oncoplot of the top 50 most frequently mutated genes in the HMCLs. Colored squares show mutated genes, while grey squares show non mutated genes. Each color represents a different type of mutations: missense (green), in frame insertion (red), frame shift deletion (orange), frame shift insertion (yellow), nonsense mutations (blue), in frame deletion (purple) and multi hit (black). Percentages above the heatmap represent mutation rate among all cell lines presenting at least one mutated gene of the tested gene list. N is the number of cell lines mutated for a given gene.](thnov09p0540g001){#F1}

![**Frequently mutated genes in HMCLs shared with MM patients at diagnosis and relapse.** Exome-seq data of 59 MM patients including 43 newly diagnosed and 16 relapsing were processed with the analysis workflow. **(A)** Oncoplot of frequently mutated genes in HMCLs (N \>= 5) shared with patients at diagnosis. **(B)** Oncoplot of frequently mutated genes in HMCLs (N ≥ 5) shared with patients at relapse. Eleven patients without detectable mutations were not included in the figure. N is the number of patients mutated for a given gene.](thnov09p0540g002){#F2}

![**Classification of HMCLs into groups. (A)** HMCLs were classified into multiple groups based on their mutation profile using multiple correspondence analysis followed by hierarchical clustering. The dendrogram shows five sub-groups with associated mutations. **(B)** HMCLs characteristics. Heatmap showing main CNV and translocations in MM for all cell lines. Blue squares, unlike grey squares, show the presence of the feature in the cell line.](thnov09p0540g003){#F3}

![**Mutations in key pathways controlling cell growth. (A)** Representation of mutated genes in the JAK-STAT pathway, PI(3)K-AKT pathway, MAPK pathway and receptors. Mutated genes are shown in squares. Gene names in light grey color are non-mutated. **(B)** Representation of mutated genes involved in cell cycle.](thnov09p0540g004){#F4}

![**HMCLs mutational portrait for genes involved in cell growth. (A)** Oncoplot of all proliferation-mutated genes. Twenty-eight cell lines out of 30 have at least one mutated gene belonging to the proliferation group. **(B)** Oncoplot of all cell cycle mutated genes. Twenty-three cell lines out of 30 have at least one mutated gene belonging to the cell cycle group.](thnov09p0540g005){#F5}

![**Mutations in DNA repair pathways and epigenetic factors. (A)** Representation of mutated genes in the main DNA repair pathways. Mutated genes are shown in filled ellipses. **(B)** Representation of mutated epigenetic factors according to the type of epigenetic modifications they generate.](thnov09p0540g006){#F6}

![**HMCLs mutational portrait for genes involved in DNA repair pathways and epigenetic factors. (A)** Oncoplot of all DNA repair mutated genes. Twenty-one cell lines out of 30 have at least one mutated gene belonging to DNA repair pathway. **(B)** Oncoplot of all mutated epigenetic factors.](thnov09p0540g007){#F7}

![**Association between mutated genes and drug response.** HMCLs have been treated with a conventional drug used in MM (Dexamethasone, IMiDs) and targeted inhibitors (TSA, SAHA, and Panobinostat). For a given drug, bar plots are the IC~50~ of the drug according to the mutated genes. The IC~50~ values in cell lines were compared using Wilcoxon test. **(A)** Mutated gene associated with drug resistance. **(B)** Mutated genes associated with drug sensitivity. N is the number of cell lines tested with a given drug and involved in the statistical test. \* : p-value \< 0.05, \*\* : p-value \< 0,01. Error bars represent mean standard deviation.](thnov09p0540g008){#F8}

![**Association between mutated genes involved in the cereblon pathway and resistance to Pomalidomide. (A)** Representation of mutated genes involved in IMiD-mediated CRL4^CRBN^ activity. Mutated genes are shown in filled ellipses. **(B)** Seven HMCLs presenting missense mutations of genes involved in the cereblon pathway as well as six HMCLs without mutations (WT) have been treated with Pomalidomide. IC~50~ of Pomalidomide for each tested HMCL is shown in the table below the heatmap. IC~50~ of mutated (Mut) and wild type (WT) HMCLs were compared using Wilcoxon test. \* : p-value \< 0.05. Error bars represent mean standard deviation.](thnov09p0540g009){#F9}
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